Evidence map›Paper›PMID 36460265›Full record

ArticleContemporary clinical trials2023

Study protocol: Behavioral economics and self-determination theory to change diabetes risk (BEST Change).

Eli W Carter, Harita S Vadari, Shelley Stoll, Baylee Rogers, Kenneth Resnicow, Michele Heisler, William H Herman, H Myra Kim, Laura N McEwen, Kevin G Volpp and 1 more

Open access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Eli W CarterDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America. Electronic address: ewcarter@med.umich.edu.
Harita S VadariDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America.
Shelley StollDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America.
Baylee RogersDepartment of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, United States of America.
Kenneth ResnicowDepartment of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, United States of America.
Michele HeislerDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America; Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, United States of America; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, United States of America; University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, United States of America.
William H HermanDepartments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI, United States of America.
H Myra KimVA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, United States of America; Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, MI, United States of America.
Laura N McEwenUniversity of Michigan, Department of Internal Medicine- Metabolism, Endocrinology, and Diabetes, United States of America.
Kevin G VolppCenter for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, PA, United States of America; Departments of Medicine and Health Care Management, University of Pennsylvania, Philadelphia, PA, United States of America.
Jeffrey T KullgrenDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States of America; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, United States of America; University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, United States of America; Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI, United States of America.
University of Michigan–Ann Arbor · USVA Ann Arbor Healthcare System · USUniversity of Pennsylvania · USVA Center for Clinical Management Research · US

Funding

Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Integrating Behavioral Economics and Self-Determination Theory to Advance Patient Engagement in Diabetes PreventionR18DK122418 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KULLGREN, JEFFREY · 2019 to 2023
$2.9M
NIDDK NIH HHS P30 DK092926NIDDK NIH HHS R18 DK122418
6 · The paper itself

Abstract

backgroundThe Diabetes Prevention Program (DPP) and metformin can prevent or delay the onset of type 2 diabetes mellitus (T2DM) among patients with prediabetes. Yet, even when these evidence-based strategies are accessible and affordable, uptake is low. Thus, there is a critical need for effective, scalable, and sustainable approaches to increase uptake and engagement in these interventions.

methodsIn this randomized controlled trial, we will test whether financial incentives and automated messaging to promote autonomous motivation for preventing T2DM can increase DPP participation, metformin use, or both among adults with prediabetes. Participants (n = 380) will be randomized to one of four study arms. Control Arm participants will receive usual care and educational text messages about preventing T2DM. Incentives Arm participants will receive the Control Arm intervention plus financial incentives for DPP participation or metformin use. Tailored Messages Arm participants will receive the Control Arm intervention plus tailored messages promoting autonomous motivation for preventing T2DM. Combined Arm participants will receive the Incentives Arm and Tailored Messages Arm interventions plus messages to increase the personal salience of financial incentives. The primary outcome is change in hemoglobin A1c from baseline to 12 months. Secondary outcomes are change in body weight, DPP participation, and metformin use. DISCUSSION: If effective, these scalable and sustainable approaches to increase patient motivation to prevent T2DM can be deployed by health systems, health plans, and employers to help individuals with prediabetes lower their risk for developing T2DM.

Indexed as

Diabetes Mellitus, Type 2MetforminPrediabetic StateAdultBody WeightEconomics, BehavioralHumansMotivationRandomized Controlled Trials as TopicMetforminBehavioral economicsDiabetes preventionRandomized controlled trialsSelf-determination theory

Identifiers

PMID36460265
PMCPMC10259647
OpenAlexW4310643054

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.